Cargando…
Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice
Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) pr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838488/ https://www.ncbi.nlm.nih.gov/pubmed/36639569 http://dx.doi.org/10.1038/s41598-023-27965-x |
_version_ | 1784869298349539328 |
---|---|
author | Haupt, Robert Baracco, Lauren Harberts, Erin M. Loganathan, Madhumathi Kerstetter, Lucas J. Krammer, Florian Coughlan, Lynda Ernst, Robert K. Frieman, Matthew B. |
author_facet | Haupt, Robert Baracco, Lauren Harberts, Erin M. Loganathan, Madhumathi Kerstetter, Lucas J. Krammer, Florian Coughlan, Lynda Ernst, Robert K. Frieman, Matthew B. |
author_sort | Haupt, Robert |
collection | PubMed |
description | Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) protein vaccine, offer greater protection from influenza virus challenge in mouse respiratory models using adult mice than standard HA:adjuvant combinations. In this study, we determined that immunization with HA + BECC adjuvants also significantly broadened the epitopes targeted on HA as compared with other adjuvants, resulting in increased titers of antibodies directed against the highly conserved HA stalk domain. Importantly, we demonstrate that BECC470 combined with an influenza virus HA protein antigen in a prime-only immunization regimen was able to achieve complete protection from challenge in a ~ 12-month-old mouse aged model. Together, this demonstrates the heightened protection provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced immune response, as compared to other adjuvants elicited by the formulation of HA with BECC470. |
format | Online Article Text |
id | pubmed-9838488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98384882023-01-15 Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice Haupt, Robert Baracco, Lauren Harberts, Erin M. Loganathan, Madhumathi Kerstetter, Lucas J. Krammer, Florian Coughlan, Lynda Ernst, Robert K. Frieman, Matthew B. Sci Rep Article Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) protein vaccine, offer greater protection from influenza virus challenge in mouse respiratory models using adult mice than standard HA:adjuvant combinations. In this study, we determined that immunization with HA + BECC adjuvants also significantly broadened the epitopes targeted on HA as compared with other adjuvants, resulting in increased titers of antibodies directed against the highly conserved HA stalk domain. Importantly, we demonstrate that BECC470 combined with an influenza virus HA protein antigen in a prime-only immunization regimen was able to achieve complete protection from challenge in a ~ 12-month-old mouse aged model. Together, this demonstrates the heightened protection provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced immune response, as compared to other adjuvants elicited by the formulation of HA with BECC470. Nature Publishing Group UK 2023-01-13 /pmc/articles/PMC9838488/ /pubmed/36639569 http://dx.doi.org/10.1038/s41598-023-27965-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Haupt, Robert Baracco, Lauren Harberts, Erin M. Loganathan, Madhumathi Kerstetter, Lucas J. Krammer, Florian Coughlan, Lynda Ernst, Robert K. Frieman, Matthew B. Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title | Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title_full | Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title_fullStr | Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title_full_unstemmed | Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title_short | Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice |
title_sort | enhancing the protection of influenza virus vaccines with becc tlr4 adjuvant in aged mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838488/ https://www.ncbi.nlm.nih.gov/pubmed/36639569 http://dx.doi.org/10.1038/s41598-023-27965-x |
work_keys_str_mv | AT hauptrobert enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT baraccolauren enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT harbertserinm enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT loganathanmadhumathi enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT kerstetterlucasj enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT krammerflorian enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT coughlanlynda enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT ernstrobertk enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice AT friemanmatthewb enhancingtheprotectionofinfluenzavirusvaccineswithbecctlr4adjuvantinagedmice |